Levi & Korsinsky Alerts Intellia Therapeutics Shareholders About Class Action Lawsuit and Critical Deadlines

Alert for Intellia Therapeutics Investors: Class Action Lawsuit

Levi & Korsinsky, LLP, a well-known law firm specializing in securities litigation, is reaching out to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA) regarding an important legal matter—a class action lawsuit. This lawsuit aims to address alleged securities fraud that may have negatively impacted Intellia investors between July 30, 2024, and January 8, 2025.

Background of the Case

The lawsuit stems from a series of misleading statements made by the defendants in relation to Intellia’s clinical trials, particularly regarding its Phase 1/2 study of NTLA-3001, which was intended to treat alpha-1 antitrypsin deficiency (AATD) associated lung disease. During this period, the company expressed optimism about starting patient dosing in the latter half of 2024, without revealing critical information about the dwindling demand for viral-based gene editing techniques, as the scientific community was shifting focus towards non-viral methods that offered cost advantages and quicker developments.

The situation escalated dramatically on January 9, 2025, when Intellia announced a reorganization of the company, including plans to cease all NTLA-3001 research and cut its workforce by 27%. This startling news revealed that the previously celebrated drug program was now deemed inefficient, resulting in a significant drop in the company's stock price from $12.02 to $10.20 between January 8 and January 10, 2025.

Who is Affected?

If you are an investor in Intellia Therapeutics and suffered financial losses attributed to the aforementioned timeline, you might be eligible to join the class action suit. It's essential to note that investors do not have to be lead plaintiffs to recover funds; they only need to show that they were affected by these events.

Next Steps for Shareholders

Shareholders should act quickly, as the deadline to apply for lead plaintiff status in this class action is April 14, 2025. Interested parties can contact Joseph E. Levi, Esq. via email or phone for further information and guidance on how to proceed.

Cost-Free Participation

It’s important to highlight that if you are part of the class, you can potentially receive compensation without facing any out-of-pocket expenses. Levi & Korsinsky assures class members that participating incurs no legal fees unless a recovery is achieved.

Why Choose Levi & Korsinsky?

With over 20 years of experience and a history of securing hundreds of millions of dollars for shareholders, Levi & Korsinsky has become a trusted name in securities litigation. The firm has a proven track record, frequently being recognized as one of the top securities litigation firms in the United States.

Need Help?

For more information about the class action or to discuss your rights as an Intellia investor, reach out to:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500

Don’t miss the opportunity to secure the redress that you might deserve as a shareholder affected by these developments. Stay informed and proactive!